Breaking News, Collaborations & Alliances

Nona Biosciences, Pfizer Enter Global ADC License Agreement

Nona will receive up to $53 million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nona Biosciences, a global biotechnology company, has entered into an exclusive license agreement with Pfizer for the global clinical development and commercialization of Nona Biosciences’ MSLN-targeted antibody-drug conjugate (ADC), HBM9033.   Nona Biosciences will receive a total of up to $53 million in upfront and near-term payments, with the potential for additional payments of up to $1.05 billion based on development and commercial milestones. Nona Biosciences is also eligible to re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters